Core Viewpoint - The article discusses an upcoming investment roadshow organized by the Zhongguancun Alliance for New Biomedical Industry and SiYu MedTech, aimed at connecting investors with projects in the biomedical and medical device sectors [4][6]. Group 1: Event Details - The roadshow will take place on December 25, 2025, at 14:00, both online via Tencent Meeting and in-person at Tsinghua Science Park [4]. - The event is free of charge and serves as a public service for alliance members, with a project vetting process in place to ensure quality participation [6]. Group 2: Target Participants - Projects eligible for the roadshow include those in the financing stages from angel round to Series C, covering fields such as biomedicine, medical devices, and medical aesthetics [4][6]. - Founders of participating projects come from backgrounds in research, medicine, and large enterprises, indicating a strong educational and professional pedigree [4]. Group 3: Investor Participation - A curated list of investors will be invited to the roadshow, including well-known firms such as Sequoia Capital, IDG, and others, ensuring that only qualified institutions with relevant investment experience are involved [7]. - After the roadshow, the organizers will facilitate connections between interested investors and project CEOs [4].

PART1 课程背景 医疗人工智能 实训营 第一期 当前，医疗AI在影像诊断、精准治疗和药物研发等场景广泛应用，但医疗机构普遍面临跨学科 人才短缺、技术落地难的挑战，制约了医疗智能化转型进程。 上海交通大学医学院联合上海交通大学生物医学工程学院、学生创新中心、附属医院等优势技 术与临床资源，针对人工智能在医疗领域快速渗透的行业趋势，聚焦医生、工程技术人员及科 研人员以及企业界对AI应用技能的迫切需求，推出医疗人工智能实训营。本课程通过系统化实 战训练，精准衔接临床需求与AI技术，为培养复合型人才提供核心支撑。 PART2 课程特色 01 临床痛点精准匹配 01 临床痛点精准匹配 直击医生在诊断、治疗，科研人员在药物研发中的数据处理与模型部署难题，提 供可直接落地的AI技能训练。 02 实战导向的完整课程体系 从AI基础、医学数据处理到临床案例实操，形成"理论-分析-应用-实操"闭环学习 路径。 03 双领域权威协同 医学专家与AI工程师联合设计并授课，内容严格遵循临床规范与技术前沿，保障 专业性与实用性。 PART3 开课信息 PART4 课程安排 图片 第一天：《人工智能基础》 结合医疗场景讲解核心算法原理 ...

Core Viewpoint - The 2025 Surgical Robotics White Paper by MedRobot focuses on the value and future direction of surgical robots, addressing the industry's evolution and the importance of these technologies in modern healthcare [6][12]. Group 1: Overview of the White Paper - The white paper is the third consecutive release by MedRobot, aiming to provide insights into the trajectory and value of surgical robots, which are becoming essential in various surgical fields [6][8]. - The document has undergone thorough proofreading and content optimization to ensure it presents a comprehensive view for industry readers [2][6]. Group 2: Key Themes - The core theme of the white paper is "value," exploring the genuine contributions of surgical robots and why they are worth investment [6][12]. - The paper will cover six perspectives that form the foundational landscape of future surgery, emphasizing that surgical robots are not merely a temporary trend but a necessary evolutionary path [7][12]. Group 3: Industry Context - Surgical robots have become significant in urology, gynecology, orthopedics, general surgery, and neurosurgery, showcasing their irreplaceable value in certain procedures [6][12]. - The white paper aims to clarify the complex viewpoints within the industry, helping stakeholders find consensus on the fundamental value of surgical robots [7][12]. Group 4: Future Aspirations - MedRobot aspires to be a connector within the industry, linking doctors, enterprises, capital, and research to advance the field of surgical robotics [8][12]. - The organization believes that as technology matures and becomes more widely adopted, surgical robots will become the new norm in surgery, contributing to a more equitable and high-quality healthcare system [8][12].

Core Insights - The article promotes the "Medical Engineering Innovation and Transformation Workshop" organized by Shanghai Jiao Tong University, aimed at fostering collaboration between doctors, engineers, and investors to address challenges in medical device innovation [2][4][23] Course Highlights - The workshop offers a unique opportunity for participants to engage in innovative thinking and explore collaboration in medical technology innovation [4] - It emphasizes the integration of medical needs with engineering solutions to create innovative medical products and facilitate their transformation into market-ready solutions [4][5] - Participants will learn the Biodesign innovation methodology, which is a global leading model for efficient transformation in medical engineering [5] Training Information - The workshop is scheduled for January 10-11, 2026, with a group price of 2500 yuan per person [6] - It includes practical training over one and a half days, focusing on the core methods and elements of medical engineering innovation and transformation [7][9] Target Audience - The workshop is suitable for various professionals, including doctors, engineering technicians, manufacturers, distributors, and investors interested in medical device innovation [9] Course Structure - The course includes sessions on medical technology innovation, intellectual property management, and practical exercises to foster interdisciplinary collaboration [10][12][15] - Participants will engage in group discussions to identify and analyze real medical industry pain points and explore potential innovative solutions [15] Expert Faculty - The workshop features a team of distinguished experts from Shanghai Jiao Tong University and the biomedical engineering field, with extensive experience in medical technology and investment [17][20] Certification - Upon completion, participants will receive a certificate from Shanghai Jiao Tong University School of Medicine and continuing medical education credits [23]

时间： 2025 年 12 月 18 日（星期四）14:30–16:00 地点： 上海交通大学医学院 规模： 15-25 人 面向对象： 医疗器械创业公司 CEO、市场 / 品牌负责人 主分享嘉宾： 思宇MedTech医疗科技媒体矩阵创始人兼主编 赵清 本次活动 围 绕 传播在企业发展中的真实作用、趋势、方法讨论 展开， 主要是帮助业内同行认识和交流。 内容包括但不限于： 创业型公司 成长期、临床驱动型公司 上市公司 / 准上市公司 不同类型企业，传播重点如何取舍？ PR 是否仍被简单理解为"发稿与曝光"？ 当预算受限时，PR 应该 做减法，还是换打法 ？ 企业传播如何从"零散内容输出"，走向 可被反复使用的认知资产 ？ 哪些内容，真正能在融资、市场推广、医院沟通等关键场景中持续发挥作用？ 何时启动宣传工作？ 对谁说、说什么、不说什么？ 传播如何真正服务于医生决策，而不仅仅是产品信息呈现？ 临床内容如何从"专业正确"走向"对决策有用"？ 延展探讨｜出海公司（讨论） 如果还有其他想讨论的内容，请在报名填表时备注。 活动形式 12月底和1月份，还将在北京、深圳召开同主题活动，欢迎关注。 报名方法： 复制如下链接到 ...

文章来源： 八大处整形概念验证中心 转载要求：可以直接转载，请在文首注明来源 过去十年，整形外科与再生医学领域的技术创新并不缺少想法，更不缺论文、专利和早 期成果。真正的难点在于：如何让这些成果跨越 " 死亡之谷 " ， 从实验室原理走向可 验证的原型，再进入量产体系，最终成为真正被临床采用、被市场认可的产品。 在这一背景下，北京八大处整形科技发展有限公司牵头建设的 八大处整形医学概念验 证中心 ，成为国内首个专注整形外科科技成果转化的专业平台。 2025 年 10 月31 日 ，在 第三届八大处整形美容产业论坛 · 主论坛中， 北京八大处整形科技发展有限公司 姚贵金总经理 系统介绍了 平台建设思路、组织架构与实践探索 ，为整形与医美行业提 供了一个可参考的 " 创新到产业化 " 路径 。 活动回顾： 科技引领整形，创新驱动未来：第三届八大处整形美容产业论坛圆满召开 圆满落幕！第三届整形外科创新转化大赛决赛 一、概念验证：创新转化的核心环节 1. 概念验证是什么？ 概念验证（Proof of Concept, PoC）是创新走向产业化的关键节点，强调以最小成本、最快速度验证技术的 科学性、可量产性与商业价值。 ...

Core Viewpoint - The article discusses the evolution and clinical significance of magnifying endoscopy, emphasizing its potential to enhance early cancer detection and the need for its widespread adoption in clinical practice [2][19]. Industry Status: The "Centralized Dilemma" of Magnifying Endoscopy - Magnifying endoscopy was first introduced in the 1990s, allowing direct observation of microvascular and glandular structures without relying on pathological slices [2][3]. - In China, the clinical usage rate of magnifying endoscopy remains low, with some regions reporting usage below 10%, limiting its effectiveness in early cancer screening [2][5]. - The technology is often viewed as an "expert tool," primarily used in specialized settings, which hinders its broader application [5][7]. Technical Breakthrough: Coexistence of "Clarity" and "Ease of Use" - The core of magnifying endoscopy lies in achieving "clarity and stability," with traditional systems requiring continuous manual adjustments that complicate operations [8][11]. - A key innovation is the introduction of a one-button automatic focusing system by KSM, which allows for automatic adjustments of focus based on image clarity, significantly reducing the operational burden on physicians [11][12]. Key Conditions for Popularization: Reduction of Operational and Cost Barriers - The simplification of operations through automatic focusing allows younger doctors to quickly master the necessary skills, shortening the learning curve [13][14]. - KSM's magnifying endoscope utilizes a shared platform architecture, making it compatible with standard endoscopes and significantly lowering procurement costs, thus facilitating its integration into routine clinical practice [15][16]. Industry Significance: From Early Screening Popularization to Domestic Innovation - The widespread adoption of magnifying endoscopy represents not just an equipment upgrade but a transformation of the diagnostic system, enhancing the accuracy of early cancer detection [16][17]. - Domestic brands are playing a crucial role in making this technology more accessible, shifting the paradigm of who can utilize advanced techniques in China [17][20].

Core Viewpoint - Kosen Technology (603626.SH) announced the sale of its wholly-owned subsidiary, Kosen Medical, to Jiangsu Yaolingke Medical Technology Co., Ltd. for 915 million RMB, marking a significant strategic shift as the company exits the medical device sector [2] Group 1: Transaction Details - The transaction is based on an income approach, with the total equity value assessed at 913 million RMB as of September 30, 2025, reflecting an increase of 615 million RMB and a growth rate of 206.45% [2] - Kosen Technology expects to recognize approximately 600 million RMB in investment income from this divestiture, which will be recorded as non-recurring gains [2] - The deal is seen as a strategic acquisition for Yaolingke, enhancing its position in the precision medical device manufacturing sector [2] Group 2: Kosen Medical's Background - Kosen Medical has established itself as a competitive player in the medical device manufacturing industry, contributing to the high premium in the sale [7] - The company has collaborated with major clients like Medtronic, Zimmer, and Johnson & Johnson, providing critical components for various medical devices [9][10] - Despite its capabilities, Kosen Medical's revenue contribution has been low, accounting for about 10% of Kosen Technology's overall revenue, indicating its role as a supplementary business [6] Group 3: Reasons for Divestiture - Kosen Technology faced significant financial pressure, reporting cumulative losses of 873 million RMB from 2023 to the first three quarters of 2025, alongside high accounts receivable of 1.17 billion RMB [13] - The differing operational models between the consumer electronics and medical device sectors led to insufficient synergy, negatively impacting the efficiency of the core business [14] - The company aims to refocus on its core business in consumer electronics and energy storage, necessitating capital for overseas expansion projects [17] Group 4: Strategic Implications - The sale reflects broader challenges faced by manufacturing companies attempting to diversify into different sectors, particularly when operational demands and resource allocation become strained [26] - The entry of LYFE Capital into the medical manufacturing space signifies a shift towards asset acquisition in the global medical device sector, moving beyond previous focuses on R&D investments [27]

近日， 创新医疗器械公司 Saluda Medical 在澳大利亚证券交易所（ASX）成功完成首次公开发行 (IPO)，共募集约 2.308 亿澳元（ 约合 1.5 亿美元，10.8 亿元人民 币 ），上市时估值约为 7.75 亿 澳元 。 公司表示，本次融资所得将主要用于推动 Evoke 系统在美国市场的商业化，加速销售基础设施建设、市场推广与品牌拓展，并支持后续产品开发及全球注册流程。 尽管融资成功，但公司上市首日股价出现较大波动 — 股价从发行价2.65 澳元 跌至约 1.48 澳元 ，市值短期缩水近 45%。有分析认为，这反映投资者对医疗器械行 业"高成长 + 长投入"模式的谨慎审视，尤其在盈利周期尚不确定的情况下，对"未来盈利可见性"的要求更高。 不管市场反应如何，这一次 IPO 对 Saluda 来说意义重大 —— 它标志着闭环神经调控技术，正从"研发与小规模应用"走向"资本市场 + 大规模商业化"的关键阶段。 # 公司介绍 Saluda 并非走"大而全"路径，而是高度聚焦 —— 它的核心竞争力集中在：神经信号 (电生理反应) 的采集与分析、基于生物信号的自动反馈调节算法、以及植入式 刺激系统的硬 ...

Core Insights - The "2026 Global Ophthalmic Innovation White Paper" will be officially released at the Second Global Ophthalmic Conference on March 19, 2026, in Beijing, focusing on key areas such as consumer ophthalmology, comprehensive diagnosis and treatment of ocular surface diseases, smart ophthalmic imaging, refractive and optometric innovations, high-end surgical platforms, and preclinical validation [1][8] - The white paper aims to systematically analyze global technological trends and China's innovation ecosystem while presenting typical enterprise cases [1][8] Chapter Summaries Chapter 1: Global Ophthalmic Innovation Landscape - Identifies six structural trends in global ophthalmic innovation [2] Chapter 2: Clinical Real Needs - Highlights unmet clinical needs and commercial opportunities in ophthalmology [3] Chapter 3: Next-Generation Ophthalmic Imaging and AI - Discusses the integration of AI in ophthalmic imaging, emphasizing the standardization and clinical embedding of imaging technologies [3] - 2026 is identified as a pivotal year for the convergence of consumerization and technological innovation in ophthalmology [3] Chapter 4: Refractive and Myopia Medical Innovations - Focuses on the upgrade of diagnosis and service scenarios in refractive and myopia medicine [4] Chapter 5: New Era of Consumer Ophthalmology - Explores market, technology, and model innovations in consumer ophthalmology [5] Chapter 6: High-End Ophthalmic Surgical Platforms - Discusses advancements in high-end surgical platforms and precision instruments [5] Chapter 7: From Prototype to Clinical - Examines the research and validation systems for ophthalmic devices [6] Chapter 8: Annual Observation of Ophthalmic Innovation Enterprises - Provides insights into notable ophthalmic companies and their innovations [6] Chapter 9: Data Insights - Analyzes capital, registration, and product launch trends in the ophthalmic sector [6] Chapter 10: Five-Year Outlook - Identifies structural opportunities for ophthalmic innovation over the next five years [6]